ECSP20083454A - Composición que comprende el oligonucleótido antisentido y su uso para el tratamiento de la distrofia muscular de duchenne - Google Patents

Composición que comprende el oligonucleótido antisentido y su uso para el tratamiento de la distrofia muscular de duchenne

Info

Publication number
ECSP20083454A
ECSP20083454A ECSENADI202083454A ECDI202083454A ECSP20083454A EC SP20083454 A ECSP20083454 A EC SP20083454A EC SENADI202083454 A ECSENADI202083454 A EC SENADI202083454A EC DI202083454 A ECDI202083454 A EC DI202083454A EC SP20083454 A ECSP20083454 A EC SP20083454A
Authority
EC
Ecuador
Prior art keywords
treatment
muscular dystrophy
duchenne muscular
composition including
including anti
Prior art date
Application number
ECSENADI202083454A
Other languages
English (en)
Spanish (es)
Inventor
Takashi Natsukawa
Tomonori Uno
Youhei Satou
Youichi Egawa
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Publication of ECSP20083454A publication Critical patent/ECSP20083454A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ECSENADI202083454A 2018-06-26 2020-12-23 Composición que comprende el oligonucleótido antisentido y su uso para el tratamiento de la distrofia muscular de duchenne ECSP20083454A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862690270P 2018-06-26 2018-06-26
US201862739386P 2018-10-01 2018-10-01

Publications (1)

Publication Number Publication Date
ECSP20083454A true ECSP20083454A (es) 2021-01-29

Family

ID=68987235

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202083454A ECSP20083454A (es) 2018-06-26 2020-12-23 Composición que comprende el oligonucleótido antisentido y su uso para el tratamiento de la distrofia muscular de duchenne

Country Status (21)

Country Link
US (2) US20210261963A1 (https=)
EP (1) EP3815696A4 (https=)
JP (3) JP7345466B2 (https=)
KR (1) KR20210023988A (https=)
CN (1) CN112399849A (https=)
AU (2) AU2019293687B2 (https=)
BR (1) BR112020026542A2 (https=)
CA (1) CA3101321A1 (https=)
CL (1) CL2020003367A1 (https=)
CO (1) CO2020015685A2 (https=)
EC (1) ECSP20083454A (https=)
IL (1) IL279692A (https=)
MX (2) MX2020013880A (https=)
MY (1) MY209148A (https=)
NZ (1) NZ770540A (https=)
PE (1) PE20210630A1 (https=)
PH (1) PH12020552078A1 (https=)
SG (1) SG11202011554PA (https=)
TW (1) TW202035692A (https=)
WO (1) WO2020004675A1 (https=)
ZA (1) ZA202007682B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210134003A (ko) 2019-02-27 2021-11-08 스톡 테라퓨틱스, 인크. 병태 및 질환의 치료를 위한 안티센스 올리고머
BR112022022889A2 (pt) 2020-05-11 2023-04-04 Stoke Therapeutics Inc Oligômeros antissentido de opa1 para tratamento de condições e doenças
MX2023012559A (es) 2021-04-30 2023-12-15 Sarepta Therapeutics Inc Métodos de tratamiento para la distrofia muscular.
JP2025509438A (ja) 2022-03-17 2025-04-11 サレプタ セラピューティクス， インコーポレイテッド ホスホロジアミデートモルホリノオリゴマーコンジュゲート
WO2023215781A1 (en) * 2022-05-05 2023-11-09 Biomarin Pharmaceutical Inc. Method of treating duchenne muscular dystrophy
EP4665407A2 (en) * 2023-02-14 2025-12-24 Stoke Therapeutics, Inc. Antisense oligomer formulations
US20240368596A1 (en) * 2023-05-05 2024-11-07 Biomarin Pharmaceutical Inc. Dystrophin exon skipping oligonucleotides

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3398378B2 (ja) 1989-12-20 2003-04-21 アンチビラルス・インコーポレイテツド リン含有キラルインターサブユニットリンケージを有する非電荷モルホリノ―基体ポリマー
JP4777777B2 (ja) 2002-11-25 2011-09-21 雅文 松尾 ｍＲＮＡ前駆体のスプライシングを修飾するＥＮＡ核酸医薬
ATE498685T1 (de) 2004-06-28 2011-03-15 Univ Western Australia Antisense-oligonukleotide zur induktion von exon- skipping sowie verfahren zur verwendung davon
EP1811024A1 (en) 2004-10-05 2007-07-25 Nippon Shinyaku Co., Ltd. Oligo double-stranded rna and medicinal composition
WO2006129594A1 (ja) 2005-05-30 2006-12-07 Nippon Shinyaku Co., Ltd. 核酸含有複合体製剤の製造方法
MX2010004955A (es) 2007-11-15 2010-06-30 Avi Biopharma Inc Metodo de sintesis de oligomeros de morfolina.
US8084601B2 (en) 2008-09-11 2011-12-27 Royal Holloway And Bedford New College Royal Holloway, University Of London Oligomers
CN112574988A (zh) 2008-10-24 2021-03-30 萨雷普塔治疗公司 用于dmd的多外显子跳跃组合物
TWI541024B (zh) * 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
CN112251436A (zh) * 2012-01-27 2021-01-22 比奥马林技术公司 治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸
RS58529B1 (sr) * 2013-03-14 2019-04-30 Sarepta Therapeutics Inc Sastavi koji preskaču egzon za tretiranje mišićne distrofije
CA2906812A1 (en) 2013-03-15 2014-09-18 Sarepta Therapeutics, Inc. Improved compositions for treating muscular dystrophy
WO2014189142A1 (ja) * 2013-05-24 2014-11-27 味の素株式会社 モルフォリノオリゴヌクレオチドの製造方法
EA201890811A1 (ru) * 2015-09-30 2018-09-28 Сарепта Терапьютикс, Инк. Способы лечения мышечной дистрофии
FR3044926B1 (fr) * 2015-12-09 2020-01-31 Genethon Outils de therapie genique efficaces pour le saut de l'exon 53 de la dystrophine

Also Published As

Publication number Publication date
ZA202007682B (en) 2024-04-24
JP7595719B2 (ja) 2024-12-06
JP2023171731A (ja) 2023-12-05
MY209148A (en) 2025-06-24
WO2020004675A1 (ja) 2020-01-02
EP3815696A4 (en) 2022-11-30
JP7345466B2 (ja) 2023-09-15
AU2025283628A1 (en) 2026-01-22
JP2025028961A (ja) 2025-03-05
IL279692A (en) 2021-03-01
SG11202011554PA (en) 2020-12-30
CO2020015685A2 (es) 2021-04-30
MX2025001486A (es) 2025-03-07
EP3815696A1 (en) 2021-05-05
AU2019293687B2 (en) 2025-10-02
JPWO2020004675A1 (ja) 2021-07-15
CL2020003367A1 (es) 2021-05-24
CA3101321A1 (en) 2020-01-02
CN112399849A (zh) 2021-02-23
MX2020013880A (es) 2021-03-09
AU2019293687A1 (en) 2021-01-07
US20210261963A1 (en) 2021-08-26
PE20210630A1 (es) 2021-03-23
PH12020552078A1 (en) 2021-05-31
TW202035692A (zh) 2020-10-01
BR112020026542A2 (pt) 2021-04-06
NZ770540A (en) 2025-12-19
KR20210023988A (ko) 2021-03-04
US20240158792A1 (en) 2024-05-16

Similar Documents

Publication Publication Date Title
ECSP20083454A (es) Composición que comprende el oligonucleótido antisentido y su uso para el tratamiento de la distrofia muscular de duchenne
CL2019000107A1 (es) Composiciones de arni contra el componente c5 del complemento y métodos para su uso.(divisional solicitud 201702014)
CL2017002636A1 (es) Composiciones que comprenden una combinación de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo.
ECSP20069416A (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
CL2017002230A1 (es) Tratamiento combinado con un agonista de tlr7 y un inhibidor del ensamblaje de la cápsida del vhb.
CL2017001488A1 (es) Benzamidas sustituidas con 1,3–tiazol–2–ilo
BR112012009376A2 (pt) composição farmacêutica, forma de dosagem farmacêutica, processo para a sua preparação, métodos de tratamento e seu uso
CO2019009215A2 (es) Sal hemi-sulfato de nucleótido para el tratamiento del virus de la hepatitis c
CO2017001493A2 (es) Kits que comprenden inhibidores tigit y agentes anticáncer
CU20150096A7 (es) Compuestos de amida y composición farmacéutica para el tratamiento de vih
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
CO2020004034A2 (es) Métodos para el tratamiento de distrofia muscular
CL2019002220A1 (es) Gasotransmisor electroquímico que genera composiciones y métodos de uso de los mismos y apósitos y sistemas de tratamiento que incorpora los mismos.
CL2016002276A1 (es) Composiciones tópicas que comprenden un extracto de coriolus versicolor para aumentar la autoinmunidad
MX2021001083A (es) Regimen posologico para anticuerpos biespecificos contra bcma-cd3.
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
CL2022001079A1 (es) Métodos y composiciones para el tratamiento del síndrome de rett
MX2015013115A (es) Nuevos regimenes de dosificacion de celgosivir para el tratamiento de dengue.
GT200900296A (es) Composición farmacéutica que comprende la combinación de un agente anti inflamatorio no esteroideo y un agente anticonvulsivante.
CL2019003463A1 (es) Composición farmacéutica y forma de dosis farmacéutica que comprenden (e)-4-(2-(aminometil)-3-fluoroaliloxi)-n-ter-butilbenzamida, proceso para su preparación, métodos para tratamiento y usos de estas.
MX2018008153A (es) Derivados de c-glicósido que tienen anillos de fenilo condensado o sales farmacéuticamente aceptables de los mismos, metodo para prepararlos y composición farmacéutica que los contiene.
ECSP15025868A (es) Composición que comprende un extracto purificado aíslado de pseudolysimachion rotundum var. subintegrum que contiene una cantidad abundante de ingrediente activo o los compuestos aislados del mismo, como un ingrediente activo para prevenir/tratar la enfermedad pulmonar obstructiva crónica, y su uso
CL2021000858A1 (es) Derivados de 4-pirazin-2-ilmetil-morfolina y su uso como medicamento
MX2022006122A (es) Oligonucleótido de doble hebra específico del gen ctgf, y una composición que comprende el mismo, para prevenir y tratar enfermedades fibróticas y enfermedades relacionadas con el sistema respiratorio.
BR112017005241A2 (pt) composto, e, composição farmacêutica.